SCHEMBL5849296

SCHEMBL5849296

CCOC(=O)c1cc2c3ccccc3n(Cc3c(F)ccc(Cl)c3F)c2cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.60
GABRP O00591 6/20 0.44
GABRD O14764 6/20 0.44
GABRA1 P14867 6/20 0.44
GABRB1 P18505 6/20 0.44
GABRG2 P18507 6/20 0.44
GABRB3 P28472 6/20 0.44
GABRA5 P31644 6/20 0.44
GABRA3 P34903 6/20 0.44
GABRA2 P47869 6/20 0.44
GABRB2 P47870 6/20 0.44
GABRA4 P48169 6/20 0.44
GABRE P78334 6/20 0.44
GABRA6 Q16445 6/20 0.44
GABRG1 Q8N1C3 6/20 0.44
GABRG3 Q99928 6/20 0.44
GABRQ Q9UN88 6/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 4/20 0.44
MAPT P10636 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216873 0.87 CNR2 (0.67) CNR2GABRPGABRDGABRA1GABRB1
SCHEMBL5849849 0.86 TP53 (0.41) CNR2GABRPGABRDGABRA1GABRB1
SCHEMBL5849331 0.84 CNR2 (0.42) CNR2ALDH1A1MAPTTSHR
SCHEMBL5849609 0.84 CNR2 (0.40) CNR2ALDH1A1MAPTTSHR
SCHEMBL7684633 0.84 CNR2 (0.63) CNR2GABRPGABRDGABRA1GABRB1
SCHEMBL5851464 0.84 HDAC6 (0.43) CNR2MAPTMEN1KMT2A
SCHEMBL5849866 0.82 CNR2 (0.66) CNR2GABRPGABRDGABRA1GABRB1
SCHEMBL2214750 0.82 CNR2 (0.71) CNR2GABRPGABRDGABRA1GABRB1
Hydrochloric Acid SCHEMBL27908737 0.81 CNR2 (0.70) CNR2GABRPGABRDGABRA1GABRB1
SCHEMBL28159270 0.81 CNR2 (0.64) CNR2GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138408-B2 HIV integrase inhibitors, pharmaceutical compositions and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-20060122211-A1 HIV integrase inhibitors, pharmaceutical compositions and methods for their use AGOURON PHARMACEUTICALS, INC. 2006-06-08 US disclosed
US-7001912-B2 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-02-21 US disclosed
EP-1590349-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER INC. (US) 2005-11-02 EP disclosed
US-20050165040-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. 2005-07-28 US disclosed
WO-2004067531-A1 HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE PFIZER INC. (US) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122211-A1 HIV integrase inhibitors, pharmaceutical compositions and methods for their use POLB, POLA1, TYMP CNR2 3950/4885GABRP 774/4885GABRD 2265/4885
US-20050165040-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use POLB, APOBEC3C, IDH3A CNR2 3906/4885GABRP 741/4885GABRD 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.